title: [Erythropoiesis stimulating agents].
abstract: Since the 90's, human erythropoietin is produced recombinantly and used clinically. There are various products from different suppliers, which differ primarily in their production but not in their half-life or effectiveness. 2001 genetically modified darbepoetin alpha was launched, which is characterized by an approximately three times longer half-life. A further extension of the half-life to 130 hours is achieved with the current continuous erythropoietin receptor activator (CERA), which therefore must be applied only once or twice a month. The indication for epoetin therapy is primarily for the symptomatic renal anemia and chemotherapy-associated anemia. Corrections of low hemoglobin levels in asymptomatic patients are not allowed. The generally recommended hemoglobin target range is 10-12 g/dl. Hb values > 13 g/dl should be avoided because they are associated with significant adverse effects and do not improve patient survival.
authors: Sektion Nephrologie, Medizinisches Universitätsklinikum Heidelberg. moritz.hoffman@med.uni-heidelberg.de
authors: Moritz
authors: M
authors: Hoffmann
authors: Vedat
authors: V
authors: Schwenger
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: C554270:EPO protein, human; D036341:Intercellular Signaling Peptides and Proteins; D011994:Recombinant Proteins; C508420:continuous erythropoietin receptor activator; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D011092:Polyethylene Glycols